Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
Provide efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to CRVO
Epistemonikos ID: ee0e109037de882a85ae74ee89646ec9163fc754
First added on: May 11, 2024